LOS ANGELES--(BUSINESS WIRE)--Jul. 29, 2014-- Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ:IPXL) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Impax's business and financial prospects.
Please contact Casey Sadler, Esquire, at (888) 773-9224 or (310) 201-9150, or at email@example.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Impax, a specialty pharmaceutical company, develops, manufactures and markets bioequivalent pharmaceutical products, and develops and markets branded products. The investigation relates to the Company's July 29, 2014, disclosure that the Food and Drug Admission (“FDA”) had uncovered potential issues at a facility where the Company would manufacture Rytary, its experimental Parkinson's disease drug. According to the Company, the FDA wants Impax to address a variety of issues at the facility, including problems with equipment, sample testing, rejection of drugs that do not meet the Company's manufacturing standards, and procedures designed to keep microorganisms out of some products. On this news, shares of Impax declined $4.27 per share, 15.23%, to close on July 29, 2014, at $23.76 per share, on unusually heavy volume.
If you purchased shares of Impax, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by toll-free telephone at (888) 773-9224 or by telephone at (310) 201-9150, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Source: Glancy Binkow & Goldberg LLP